Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial-Reference-Cited by-同舟云学术

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Published:2017-10 Issue:10 Volume:18 Page:1397-1410
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Seddon Beatrice,Strauss Sandra J,Whelan Jeremy,Leahy Michael,Woll Penella J,Cowie Fiona,Rothermundt Christian,Wood Zoe,Benson Charlotte,Ali Nasim,Marples Maria,Veal Gareth J,Jamieson David,Küver Katja,Tirabosco Roberto,Forsyth Sharon,Nash Stephen,Dehbi Hakim-Moulay,Beare Sandy

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial;Judson;Lancet Oncol,2014

2. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients;Karavasilis;Cancer,2008

3. PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma;Ryan;J Clin Oncol,2016

4. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial;Tap;Lancet Oncol,2017

Cited by 369 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Doxorubicin and trabectedin for recurrent leiomyosarcoma – A case report;Gynecologic Oncology Reports;2024-10

2. Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma;New England Journal of Medicine;2024-09-05

3. New strategies in soft tissue sarcoma treatment;Journal of Hematology & Oncology;2024-09-02

4. Effect of palliative radiation dose on symptom response in metastatic sarcomas;Clinical and Translational Radiation Oncology;2024-09

5. Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy;BMC Cancer;2024-08-20